Sign In
Buy DSNKY
$15.23
-0.94 (-5.81%)
At Close: Jun 03, 2026
TOKYO--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) and AstraZeneca's (LSE/STO/NYSE: AZN) Datroway® (datopotamab deruxtecan-dlnk) has been approved in the U.S. for the treatment of adult patients with
Daiichi Sankyo Company, Limited (DSNKY) Q4 2026 Earnings Call Transcript
04:20pm, Monday, 11'th May 2026
Daiichi Sankyo Company, Limited (DSNKY) Q4 2026 Earnings Call Transcript
Daiichi Sankyo Unveils New Five-Year Business Plan Focused on Oncology Leadership and Innovation
02:30am, Monday, 11'th May 2026
TOKYO--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) today revealed its next Five-Year Business Plan (FY2026 - FY2030) that outlines how the company plans to deliver more than 2.3 trillion yen in oncolo
Waiv Enters Collaboration with Daiichi Sankyo to Deliver AI-Derived Biomarkers for ADC Program
08:00am, Wednesday, 06'th May 2026
PARIS--(BUSINESS WIRE)--Waiv, formerly Owkin Dx, a Paris-based company catalyzing AI precision testing, today announced it has entered a collaboration with Daiichi Sankyo (TSE: 4568) to lead digital p
Interna Therapeutics Announces Research Collaboration with Daiichi Sankyo to Advance MNM-Based Targeted Delivery Technologies
05:48am, Thursday, 16'th Apr 2026
PETACH TIKVA, Israel, April 16, 2026 /PRNewswire/ -- Interna Therapeutics, a clinical stage biotechnology company advancing its Molecular Nano Motor (MNM) intracellular delivery platform, today announ
Wayfinder Biosciences Advances Collaboration with Daiichi Sankyo on Key Neurodegeneration Target to Second Phase
09:04am, Wednesday, 15'th Apr 2026
SEATTLE, April 15, 2026 /PRNewswire/ -- Wayfinder Biosciences, a biotechnology company using small molecules to target undruggable proteins at the RNA level, today announced the advancement to the sec
NEWTON, Mass.--(BUSINESS WIRE)-- #4DPath--4D Path Announces Collaboration with Daiichi Sankyo to Advance AI-Driven Predictive Biomarkers for an Antibody Drug Conjugate Program.
HAMBURG, Germany & MUNICH--(BUSINESS WIRE)--GAIA and Daiichi Sankyo Europe Enter Exclusive Partnership to Launch Next-Generation Digital Therapeutic for Cardiovascular Care in Europe.
New Strong Sell Stocks for February 25th
05:35am, Wednesday, 25'th Feb 2026
DSNKY, LPX and RAL have been added to the Zacks Rank #5 (Strong Sell) List on February 25, 2026.
Daiichi Sankyo: Hit On Multiple Fronts, But Shares Look Undervalued
05:00am, Tuesday, 24'th Feb 2026
Daiichi Sankyo shares are potentially deeply undervalued, but the near-term outlook hinges on pivotal clinical trial outcomes, notably the AVANZAR study. Enhertu continues to grow well, and Datroway i
SylamoreBio Announces Research Collaboration With Daiichi Sankyo to Advance SyLEC™ Delivery Technology
07:00am, Monday, 23'rd Feb 2026
JONESBORO, Ark.--(BUSINESS WIRE)--SylamoreBio, a biotechnology company pioneering advanced therapeutic delivery to the central nervous system (CNS) and other recalcitrant tissues, today announced it h
Daiichi Sankyo Appoints John Tsai, MD as Global Head of R&D
07:00pm, Thursday, 19'th Feb 2026
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo Company, Limited (TSE: 4568) has appointed John Tsai, MD to succeed Ken Takeshita, MD, who is stepping down as Global Head of R&D, effectiv
WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, the developer of the leading AI foundation model for tumor and immune biology, today announced a strategic collaboration with Daiichi Sankyo (TSE: 4568). T
DS3790 Enters Clinical Development as First DXd ADC in Hematology from Industry-Leading ADC Portfolio of Daiichi Sankyo
07:00am, Wednesday, 04'th Feb 2026
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--The first patient has been dosed in a first-in-human phase 1/2 trial evaluating DS3790 in patients with relapsed or refractory B-cell non-Hodgkin lymphoma
Daiichi Sankyo Company, Limited (DSNKY) Q3 2026 Earnings Call Transcript
04:42am, Friday, 30'th Jan 2026
Daiichi Sankyo Company, Limited (DSNKY) Q3 2026 Earnings Call Transcript
